baber/WOPTO huggingface dataset:
Patent NZ-593625-A (NZ)
Title: Auxiliary tank and mains water supply system
Inventor: GRAY IAN
IPC: E03B3/02
Filed: 2009-12-01
Abstract: Disclosed is a water supply system that supplies water to a plumbing system from either a mains supply, or an auxiliary supply. In a default state, a shuttle valve is pressure balanced and couples water from the mains supply to the plumbing system via mains inlet port and outlet port, and in another state the shuttle valve is pressure unbalanced and moved so that auxiliary water is coupled to the plumbing system via an auxiliary inlet port and the outlet port of the shuttle valve. Water is drawn from an auxiliary tank and coupled to the plumbing system when two conditions exist, namely when water is demanded, as sensed by flow sensor, and when water is available from the auxiliary supply, as sensed by float system. Water pressure at the auxiliary inlet port causes the shuttle to move from the default state and couple water from the auxiliary inlet port to the outlet port and thus to the plumbing system. When either of the two conditions are not met, the shuttle valve remains in the default state and couples mains water from the mains inlet port to the outlet port and thus to the plumbing system. An electronic controller is included with the system.
Patent NZ-599060-A (NZ)
Title: Improved device and method for delivery of a medicament
Inventor: MURUGESAN THANGARAJU
IPC: A24F42/10
Filed: 2010-08-31
Abstract: A device for delivering nicotine to a subject, comprises a housing. The housing comprises an inlet 1410 and an outlet in communication with each other and adapted so that a gaseous carrier may pass into the housing through the inlet 1410, through the housing and out of the housing through the outlet. The device comprises in series from inlet 1410 to outlet a first internal area in communication with the inlet and a second internal area in communication with the first internal area. The first internal area comprises a delivery enhancing compound source 1500, and the second internal area comprises a nicotine source 1420. The delivery enhancing compound source 1500 comprises an inorganic acid or a carboxylic acid 1430. The nicotine source 1420 comprises nicotine and an electrolyte forming compound, both in an aqueous solution. The electrolyte forming compound is an Alkali metal hydroxide, an Alkali metal oxide, an Alkaline earth metal oxide, an Alkaline earth metal hydroxide, or a combination thereof.
Patent NZ-599302-A (NZ)
Title: Preventing diseases in infants delivered via caesarean section
Inventor: SCHMITT JOACHIM
IPC: A23L33/00
Filed: 2006-10-06
Abstract: Patent No. 599302 Disclosed is the use of a composition comprising non-digestible oligosaccharides and comprising at least galactooligosaccharides, excluding human milk, for the manufacture of a composition for treatment and/or prevention of 5 deficiencies in the intestinal flora of infants delivered via caesarean section.
Patent NZ-600121-A (NZ)
Title: A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
Inventor: GAO GUANGPING
IPC: C12Q/
Filed: 2002-11-12
Abstract: 600121 Discloses an adeno-associated virus (AAV) comprising an AAv9 capsid having a sequence identity of amino acids 1-736 of SEQ ID NO: 100 or a sequence having at least 95% identity therewith; and a minigene having AAV inverted terminal repeats (ITRs) and a heterologous gene operably linked to regulatory sequences which direct its expression in a host cell. Also discloses capsid proteins within SEQ ID NO: 5.
Patent NZ-602255-A (NZ)
Title: Method for producing soluble recombinant interferon protein without denaturing
Inventor: ALLEN JEFFREY
IPC: C07K14/555
Filed: 2011-03-02
Abstract: 602255 Discloses a method for producing and extracting a recombinant Type 1 interferon protein, the method comprising expressing the recombinant interferon in E.coli or Pseudomonas, lysing the host cell, obtaining an insoluble and soluble fraction, obtaining an extraction pellet and supernatant from the insoluble fraction wherein the recombinant protein in the extract supernatant is present in soluble form.
Patent NZ-603345-A (NZ)
Title: Stabilized ophthalmic galactomannan formulations
Inventor: MEADOWS DAVID L
IPC: A61K9/08
Filed: 2011-05-04
Abstract: Disclosed is a viscosity-stabilized ophthalmic formulation comprising a galactomannan, borate, and sorbitol; wherein said galactomannan is guar or hydroxylpropyl guar; wherein said galactomannan is present at a concentration of about 0.1 w/v% to about 2.0 w/v% and said borate is present at a concentration of about 0.2 w/v% to about 2.0 w/v%; wherein sorbitol is present at a concentration of about 0.5 w/v% to about 5.0 w/v%; and wherein the sorbitol stabilizes the viscosity of the formulation. Also disclosed is a method of stabilising an ophthalmic formulation with sorbitol and the use of an ophthalmic formulation as an eye lubricant or for administering pharmaceutical active agents to the eye.
Patent NZ-607670-A (NZ)
Title: Theobromine in combination with an expectorant or a mucolytic for use in therapy
Inventor: BANNISTER ROBIN MARK
IPC: C07D473/10
Filed: 2011-08-25
Abstract: This disclosure relates to an agent consisting of theobromine and either an expectorant or a mucolytic to use in the therapy of a cough. The expectorant may be ambroxol, ammonium bicarbonate, ammonium carbonate, bromhexine, calcium iodide, carbocysteine, guaiacol, guaicacol benzoate, guaiacol carbonate, guaiacol phosphate, guaifenesin, guaithylline, hydriodic acid, iodinated glycerol, potassium guaiacolsulfonate, potassium iodide, sodium citrate, sodium iodide, 20 storax terebene, terpin, trifolium, althea root, antimony pentasulfide, creosote, Ipecacuanha (syrup of ipecac), levoverbenone, senega or tyloxapol and the mucolytic may be acetylcysteine, 25 bromhexine, carbocysteine, domiodol, erdostine, letostine, lysozyme, mecysteine hydrochloride, mesna, sobrerol, stepronin, tiopronin, tyloxapol, ambroxol, ammonium chloride, dornase alfa, eprazinone, erdosteine, letosteine or neltenexine.
Patent NZ-619867-A (NZ)
Title: Composition with improved digestibility of proteins
Inventor: TIMMER-KEETELS CHRISTINA JOSEPHINA ANTONIA MARIA
IPC: A23L33/00
Filed: 2012-07-13
Abstract: Disclosed is a method to produce a dairy based food composition comprising milk protein with a furosine content lower than 0.7 g/100g protein, and a Fast index lower than 20 comprising the steps (a) Treating the milk such that at least 98% of the pathogens is removed (b) Treating the milk with a microfilter of a poresize of 0.01-2 micron, at a temperature of from 0 to 25 °C, to obtain at least a casein rich fraction and a serum protein rich fraction, wherein the milk is subjected to a heating treatment before or after the microfiltration and wherein during the production of the food composition the milk and products obtained from the milk are not subjected to a heat treatment at a temperature above 90 °C, and wherein the serum protein rich fraction and/or the casein rich fraction is processed into a food composition.
Patent NZ-624907-A (NZ)
Title: Dispenser cap arrangement
Inventor: DUIGNAN CATHAL
IPC: B65D39/00
Filed: 2012-10-31
Abstract: The present invention relates to a dispenser cap arrangement for enclosing a portion of a dispenser of a medicament. In particular, the present invention relates to a dispenser cap arrangement, a dispenser cap a dispenser cap closure device, a method of closing a dispenser, and a closure arrangement. The dispenser cap arrangement comprises a dispenser cap (71) comprising a hollow body having a lower open end for engaging with a body portion of a dispenser, and an upper open end for receiving a cap closure device for closing the upper open end, the upper open end comprising an engageable portion; and a cap closure device, comprising: an upper cap closure portion (101) for engaging with the upper open end of the dispenser cap to close the upper open end of the dispenser cap; a lower cap closure portion (102) for engaging with the engageable portion to secure the cap closure device to the dispenser cap; and a bistable portion (111, 112, 113) connecting the upper cap portion and the lower cap closure portion, the bistable portion being switchable between a first stable form in which the bistable portion is extended, and a second stable form in which the bistable portion is collapsed, wherein, when the bistable portion is in the second stable form, the upper cap closure portion engages with the upper open end of the dispenser cap to close the dispenser cap.
Patent NZ-626086-A (NZ)
Title: Feeder mixer with magnet for extracting metals from the feed
Inventor: JOHN CLOSE
IPC: A01F29/00
Filed: 2014-07-01
Abstract: Apparatus 10 for mixing and supplying feed materials for animals comprises a tub 13 having a peripheral wall defining an open top 13A into which the feed materials can be supplied for mixing and a base 13C, and at least one mixing auger 14 mounted in the tub 13 so as to stand upwardly from the base. The mixing auger 14 has a rotatable upstanding core member 15 that carries a peripheral flight 17 for rotation about an upstanding axis of the core member 15. The tub 13 has at least one adjustable restricting element 20 on the peripheral wall positioned at a height on the peripheral wall aligned with the mixing auger 14. The at least one restricting element 20 extends inwardly from the peripheral wall so as to engage and restrict movement of the feed material as the feed material is carried around the peripheral wall of the tub 13 by the mixing auger 14. The restricting element 20 has mounted thereon a magnet 30 for attracting and collecting metallic materials in the feed materials.
Patent NZ-630999-A (NZ)
Title: A lighting fixture and lighting system
Inventor: JACKSON JAMES WILLIAM
IPC: H05B43/00
Filed: 2014-09-11
Abstract: Disclosed is a light fixture (10) for connecting to an electrical cable (12) and a light system. The disclosure notes that temporary lighting systems can be labour-intensive during installation as each lighting fixture must be individually soldered and/or connected by screw terminals to the conductors of the cable and they are not easily customised. The lighting fixture (10) comprises a main body (14a, 14b), a connector pin or pins (24), a seal or seals (26), a clamping assembly (20a, 20b), a light holder (30) and an outer enclosure (28a, 28b). The main body (14a, 14b) provides an open passage (18) through which the electrical cable (12) may extend. The connector pin or pins (24) protrude into the passage (18) and are configured to pierce into and terminate with the cable (12). The seal or seals (26) encapsulate each pin (24) to provide a sealed connection of the pins (24) into the cable (12). The clamping assembly (20a 20b) is realisably coupled to the main body (14a, 14b) and encloses the passage (18) and clamps the cable (12) within the passage (18) to the main body (14a, 14b). The light holder (30) is mounted to or within the main body (14a, 14b) and is electrically connected to the connector pin or pins (24). The light holder (30) retains and receives a light element. The outer enclosure (28a, 28b) is mounted to the main body (14a, 14b) and surrounds and encloses any light element installed in the light holder (30).
Patent NZ-712033-A (NZ)
Title: Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
Inventor: LIU NINGSHU
IPC: A61K31/52
Filed: 2014-04-04
Abstract: - use of a 2,3-dihydroimidazo[l,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more fu rther active agents, for the preparation of a medicament for the treatment or prophylaxis of non-Hodgkin’s lymphoma (NHL), particularly 1st line, 2nd line, relapsed, refractory, indolent or agressive non-Hodgkin’s lymphoma (NHL), in particular follicular lymphoma (FL), chronic lymphocytic leukaemia (CLL), marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), transformed lymphoma (TL), or peripheral T-cell lymphoma (PTCL); - combinations of a) said compound and b) one or more further active agents; - a pharmaceutical composition comprising said compound as a sole active agent for the treatment of non-Hodgkin’s lymphoma (NHL), particularly 1st line, 2nd line, relapsed, refractory, indolent or agressive non-Hodgkin’s lymphoma (NHL), in particular follicular lymphoma (FL), chronic lymphocytic leukaemia (CLL), marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), transformed lymphoma (TL), or peripheral T-cell lymphoma (PTCL); - a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; - use of biomarkers involved in the modification of the expression of PI3K isoforms, BTK and IKK,, BCR activation, BCR downstream activation of NFKB pathway, c-Myc, EZH2, for predicting the sensitivity and/or resistance of a cancer patient to said compound and providing a rationale-based synergistic combination as defined herein to increase sensitivity and/or to overcome resistance; and - a method of determining the level of a component of one or more of the expression of PI3K isoforms, BTK and IKK„ BCR activation, BCR downstream activation of NFKB pathway, c-Myc, EZH2.
Patent NZ-722413-A (NZ)
Title: Dihydropyrrolopyridine inhibitors of ror-gamma
Inventor: DILLARD LAWRENCE
IPC: C07D471/04
Filed: 2015-01-30
Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
Patent NZ-722418-A (NZ)
Title: Synergistic fungicidal mixtures and compositions for fungal control
Inventor: OWEN W JOHN
IPC: A01N43/54
Filed: 2014-12-30
Abstract: The present invention relates to a synergistic fungicidal mixture comprising a fungicidally effective amount of the compound of Formula I: 5-fluoro-4-imino-3-methyl-1-tosyl-3,4-dihydropyrimidin-2-(1H)-one, and at least one succinate dehydrogenase inhibitor that provides synergistic control of selected fungi. This invention also relates to synergistic fungal composition containing this mixture.
Patent NZ-734749-A (NZ)
Title: Improvements in and relating to animal effluent treatment system
Inventor: HONG JIE DI
IPC: C02F103/20
Filed: 2016-06-20
Abstract: A method of treating animal effluent including the steps of: first, adding a coagulant to the animal effluent to be treated as pre-treatment; and secondly, (optionally) adding a coagulant aid and/or alkali and/or disinfectant (e.g. sodium hypochlorite) to the pre-treated animal effluent of step a).
Patent NZ-737536-A (NZ)
Title: Substituted benzamides and methods of use thereof
Inventor: LI JUN
IPC: C07D211/22
Filed: 2016-05-20
Abstract: The invention provides substituted benzamide compounds, a representative example of which is shown, having activity as sodium channel (e.g., NaV1.7) inhibitors that are useful in the manufacture of medicaments for treating sodium channel-mediated diseases or conditions, such as pain, as well as other diseases and conditions associated with the mediation of sodium channels, and pharmaceutical compositions containing such compounds.
Patent NZ-747778-A (NZ)
Title: Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist
Inventor: KAMBHAMPATI RAMASASTRI
IPC: A61P25/28
Filed: 2016-08-03
Abstract: The present invention relates to pure 5-HT6 receptor antagonists selected from 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole; 1-[(4-Fluorophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole; or 1-[(4-Isopropylphenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole, or their pharmaceutically acceptable salt(s) thereof, in combination with or as adjunct to a N-Methyl-D-aspartate (NMDA) receptor antagonist and their use in the treatment of cognitive disorders. The invention further relates to the pharmaceutical composition containing the said combination, and the use of the combination in an improved combination therapy for the treatment of cognitive disorders, such as Alzheimer’s disease, schizophrenia, Parkinson’s disease, Lewy body dementia, vascular dementia or frontotemporal dementia.
Patent NZ-757365-A (NZ)
Title: Fgfr3 binding molecules
Inventor: SILACCI MELKKO MICHAELA
IPC: C07K16/28
Filed: 2018-04-03
Abstract: The present invention relates to a polypeptide binding to fibroblast growth factor receptor 3 iso forms 3b and 3c (FGFR3b and FGFR3c), wherein the polypeptide comprises an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDYEVYGPTPMLSFHKGEKFQIL(X1)(X2)(X3) (X4)GPYWEARSL(X5)TGETG(X6)IPSNYVAPVDSIQ (SEQ ID NO: 1), wherein amino acid positions (X1) to (X6) may be any amino acid sequence; (b) an amino acid sequence which is at least 95% identical to the amino acid sequence of (a), wherein the identity determination excludes amino acid positions (X1) to (X6) and provided that the amino acid sequence EVYGPTPM (SEQ ID NO: 2) in amino acid positions 12 to 19 of SEQ ID NO: 1 is conserved and the amino acids P and Y in amino acid positions 37 and 38 of SEQ ID NO: 1 are conserved; (c) GVTLFVALYDYEVMSTTALSFHKGEKF QILSQSPHGQYWEARSLTTGETG(X6)IPSNYVAPVDSIQ (SEQ ID NO: 19), wherein the amino acid position (X6) may be any amino acid; and (d) an amino acid sequence which is at least 95% identical to the amino acid sequence of (c), wherein the identity determination excludes amino acid position (X6) and provided that the amino acid sequences EVMSTTA (SEQ ID NO: 20) in amino acid positions 12 to 18 of SEQ ID NO: 19 and SQSPH (SEQ ID NO: 21) in amino acid positions 31 to 35 of SEQ ID NO: 19 are conserved and the amino acids Q and Y in amino acid positions 37 and 38 of SEQ ID NO: 19 are conserved.
Patent NZ-765241-A (NZ)
Title: Conduit for use in a respiratory apparatus
Inventor: ROW NATHAN JOHN
IPC: H05B3/56
Filed: 2007-11-08
Abstract: A conduit arrangement for use in delivering pressurized breathable gas to a patient. The conduit arrangement includes a first cuff configured to be attached to a respiratory therapy treatment system, the first cuff comprising a tubular air inlet portion and an electrical connector portion including three electrical terminals configured to engage an electrical connector of the respiratory therapy treatment system; a second cuff (56) comprising a tubular air outlet configured to pass the pressurized breathable gas towards an inlet of a patient interface (5); a structure (air delivery hose 4) forming a passage for the pressurized breathable gas from the tubular air inlet of the first cuff towards the tubular air outlet of the second cuff; and a helical rib (4b) on an outer surface of the structure forming the passage. The rib contains a pair of heating wires (4d, 4e) and a signal wire (4c), which extend at least the length of the structure forming the passage. The helical rib is in contact with the outer surface of the structure forming the passage. The heating wires are configured to heat the pressurized breathable gas flowing through the passage. The signal wire is configured to convey a signal indicative of a condition within the passage. A sensing device is positioned within the second cuff, the sensing device being configured to output the signal indicative of a condition inside the conduit arrangement. Each of the heating wires and the signal wire is connected to a corresponding one of the three electrical contacts of the electrical connector. The pair of heating wires and the signal wire are positioned in a side-by-side arrangement within the helical rib so that the pair of heating wires and the signal wire form a row in which one of the wires is between the other two wires. The three electrical terminals are positioned in a side-by-side arrangement that forms a row in which one of the electrical terminals is between the other two electrical terminals. The first cuff and the second cuff have different shapes.
Patent NZ-785739-A (NZ)
Title: Aryl- or heteroaryl-substituted benzene compounds
Inventor: KUNTZ KEVIN
IPC: C07D213/64
Filed: 2012-04-13
Abstract: Disclosed are N-((2-oxo-1,2-dihydropyridin-3-yl)methyl)-biphenyl-3-carboxamide derivatives of Formula (I) or a pharmaceutically acceptable salts thereof. Also disclosed is a pharmaceutical composition comprising a compound as defined above or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, for treating a cell proliferative disorder or a precancerous disorder, wherein the cell proliferative disorder is not cancer.
Patent PT-101084-A (PT)
Inventor: BRIDGES RUSSELL PEARCE
IPC: A61F13/496
Filed: 1992-11-20
Abstract: A unitary disposable garment, such as disposable training pants, having a high degree of stretch in the cross-machine direction and fitting a broad range of wearer sizes. The unitary disposable garment is manufactured from a chassis and has a waist opening, two leg openings and a pair of side seams which join the front portion of the chassis to the rear portion of the chassis. The unitary disposable garment preferably has an absorbent assembly, i.e. an absorbent insert, secured to the inner layer of the chassis. The chassis from which the unitary disposable garment is manufactured, has four elasticized ear flaps; each ear flap is elasticized by securing an elastomeric element thereto and mechanically stretching the ear flap and the elastomeric element such that the ear flap is elastically extensible in the direction of initial stretching. The front portion of the chassis is then joined to the rear portion of the chassis on each side of the disposable garment by a seam.
Patent PT-104616-A (PT)
Title: Sistema de embalagem especial com suporte à refeição
Inventor: FERNANDES ISABEL MARIA RODRIGUES BARRETO
IPC: B65D5/20
Filed: 2009-06-04
Abstract: O PRESENTE INVENTO REFERE-SE A UM SISTEMA DE EMBALAGEM (1) PARA CONTER E TRANSPORTAR ALIMENTOS SÓLIDOS E LÍQUIDOS QUE PERMITE TORNAR-SE NUM APOIO AUTÓNOMO A UMA REFEIÇÃO PARA O CONSUMO DOS ALIMENTOS NELE CONTIDOS (1Β). ESTE SISTEMA É CONSTITUÍDO POR UMA SÓ PEÇA (1Α) DE CARTOLINA PLANIFICADA E ARMADO POR ENCAIXE. O SISTEMA DE EMBALAGEM QUANDO MONTADO TEM UMA ZONA INTERNA DE ARMAZENAMENTO, UMA ABERTURA PARA O ENCAIXE E FIXAÇÃO DE UMA BEBIDA (GARRAFA, LATA OU COPO) E UMA ZONA INFERIOR COM ABAS PARA ENCAIXAR ENTRE OS MEMBROS INFERIORES DO UTILIZADOR (QUANDO SENTADO), PERMITINDO UM APOIO FIXO À REFEIÇÃO. A INVENÇÃO É DIRIGIDA A UM MERCADO/COMÉRCIO DE PEQUENAS OU RÁPIDAS REFEIÇÕES.
Patent PT-107613-A (PT)
Title: Processo de extrusão de emulsões cerâmicas
Inventor: RIBEIRO MANUEL JOAQUIM PEIXOTO MARQUES
IPC: C04B35/10
Filed: 2014-04-09
Abstract: A METODOLOGIA PROPOSTA PARA PROCESSAR MATERIAIS CERÂMICOS CELULARES POROSOS CONSISTE NA EXTRUSÃO DE EMULSÕES CERÂMICAS PREPARADAS POR EMULSIFICAÇÃO DE UMA SUSPENSÃO CERÂMICA EM LÍQUIDOS ORGÂNICOS, USANDO AGENTES SURFATANTES E GELIFICANTES PARA GARANTIR A ESTABILIDADE DA EMULSÃO. A SOLIDIFICAÇÃO DA PARAFINA IMPOSSIBILITA A COALESCÊNCIA DAS GOTAS DE FASE DISPERSA, PERMITINDO CONTROLAR AS CARACTERÍSTICAS MICROESTRUTURAIS DA MATRIZ DURANTE A EXTRUSÃO E A SECAGEM. ESTUDOU-SE O PROCESSO DE EXTRUSÃO DE CERÂMICOS CELULARES COM DIFERENTES MATÉRIAS-PRIMAS. APÓS PIRÓLISE DA FASE ORGÂNICA DISPERSA E POSTERIOR SINTERIZAÇÃO AS AMOSTRAS CERÂMICAS RESULTANTES POSSUEM AS SEGUINTES CARACTERÍSTICAS: I) POROSIDADES 40-85 %; II) TAMANHO MÉDIO DE CAVIDADE ENTRE 1 E 100 UM; III) PERMEABILIDADE A LÍQUIDOS NA GAMA 10-5-10-7 M S-1 E A GASES ENTRE 5X10-10 A 10-14 M2; IV) RESISTÊNCIA MECÂNICA À COMPRESSÃO ATÉ 70 MPA E À FLEXÃO ATÉ 40 MPA.